For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 776,410 | 553,657* | 432,113 | - |
| Sales and marketing | 4,278 | 18,291.5* | 45,285 | 68,834 |
| Research and development | - | - | - | 381,061 |
| General and administrative | 1,393,060 | 1,634,114* | 893,305 | 851,195 |
| Total operating expenses | 2,173,748 | 2,206,062.5 | 1,370,703 | 1,301,090 |
| Operating loss | -2,173,748 | -2,206,062.5* | -1,370,703 | -1,301,090 |
| Other income | 351 | 17,806* | - | - |
| Digital asset staking compensation | 11,060 | 1,280.25* | - | - |
| Changes in fair value of warrant liability | - | - | - | 62,112 |
| Unrealized gain on change in fair value of digital assets | 738,177 | -248,790.25* | - | - |
| Other income (expense) | - | - | 42,018 | 13,066 |
| Warrant expense | - | 166,257.5* | - | - |
| Realized gain on change in fair value of digital assets | 121,584 | - | - | - |
| Changes in fair value of warrant liability | 8,857 | 192,579.5* | 267,274 | - |
| Total other expenses | - | - | - | 75,178 |
| Total other (expenses) income | 862,315 | -588,541* | -225,256 | - |
| Loss from operations before income taxes | -1,311,433 | -2,794,603.5 | -1,595,959 | -1,225,912 |
| Provision for income taxes | - | - | - | 0 |
| Net loss | -1,311,433 | -2,794,603.5 | -1,595,959 | -1,225,912 |
| Basic EPS | -1.09 | -3.438 | -2.1 | - |
| Diluted EPS | -1.09 | -3.438 | -2.1 | - |
| Basic Average Shares | 1,199,586 | 812,822 | 761,218 | - |
| Diluted Average Shares | 1,199,586 | 812,822 | 761,218 | - |
ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Inc. (NDRA)